Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
5 hedge funds and large institutions have $9.91M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$4.03M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$3.85M |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$1.01M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$1.01M |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$30.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $4.02M | +$4.03M | +399,999 | New |
|
|
GPCM
2
Granite Point Capital Management
Boston,
Massachusetts
| $3.85M | +$3.85M | +382,693 | New |
|
|
SCM
3
Suvretta Capital Management
New York
| $1M | +$1.01M | +99,999 | New |
|
|
RCM
4
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| $1M | +$1.01M | +100,000 | New |
|
|
WAM
5
Wolverine Asset Management
Chicago,
Illinois
| $30K | +$30.2K | +3,000 | New |
|
EUCR Hedge Fund Activity: Q4 2020 in Review
5 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q4 2020, worth a combined $9.91M.
Buyers outnumbered sellers: 5 funds opened new EUCR positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $4.03M.
- 5 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $9.91M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q4 2020.
- 5 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q4 2020 and 0 closed out, a net change of +5 holders.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q4 2020 was Hudson Bay Capital Management, an estimated $4.03M added.
Based on aggregated 13F filings for Q4 2020.